LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

Akari Therapeutics Plc

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERAKTX
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / AKTX COVERAGE

What’s moving Akari Therapeutics Plc now

Current reporting with the operating signal separated from the noise.

01
Akari Therapeutics Plc: Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics

Akari Therapeutics Plc: Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics

The story matters when it changes Akari Therapeutics Plc’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Akari Therapeutics Plc: Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board

Akari Therapeutics Plc: Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board

The story matters when it changes Akari Therapeutics Plc’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
ADR (AKTX) Price Target Increased by 45.45% to 81.60

Akari Therapeutics Plc

The story matters when it changes Akari Therapeutics Plc’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest AKTX filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-19 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-13 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-03-30 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-07-02 · Period 2026-06-30SEC ↗8-KMaterial company eventFiled 2026-06-26 · Period 2026-06-23SEC ↗8-KMaterial company eventFiled 2026-05-22 · Period 2026-05-20SEC ↗6-KOfficial SEC filingFiled 2023-12-01 · Period 2023-12-01SEC ↗6-KOfficial SEC filingFiled 2023-11-16 · Period 2023-11-16SEC ↗
EARNINGS / QUARTERLY TRACKER

Akari Therapeutics Plc, quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.